头孢哌酮-舒巴坦联合左氧氟沙星治疗社区获得性肺炎的临床观察  

Clinical Investigation on Cefoperazone/Sulbactam and Levofloxacin in the Treatment of Community-Acquired Pneumonia

作　　者：雷震[1] 左莹[1] 

机构地区：[1]川北医学院附属医院内科,四川南充637000

出　　处：《中国医药指南》2013年第14期53-54,共2页Guide of China Medicine

摘　　要：目的观察头孢哌酮-舒巴坦联合左氧氟沙星治疗社区获得性肺炎（CAP）的临床疗效和不良反应。方法将60例CAP患者,随机分为两组,治疗组为头孢哌酮-舒巴坦联合左氧氟沙星组（n=30）,对照组为单纯用头孢哌酮-舒巴坦（n=30,疗程均为10~14d,观察两组患者的临床疗效和不良反应。结果治疗组总有效率为96.75%,对照组的总有效率为84.56%,两组的临床疗效比较差异有统计学意义（P〈0.05）。治疗组不良反应发生率10.79%,对照组不良反应发生率8.36%,两组不良反应发生率比较差异无统计学意义（P〉0.05）。结论头孢哌酮-舒巴坦联合左氧氟沙星治CAP可提高疗效,且耐受性良好。Objective To evaluate the efficacy and safety of cefoperazone/sulbactam and levofloxacin in the treatment of community-acquired pneumonia（CAP）. Methods 60 patients with CAP were randomly divided into two groups. Treatment group： the patients were treated with cefoperazone/ sulbactam and levofloxacin. Control group： the patients were treated with cefoperazone/sulbactam alone. Both groups were treated for 10-14 days. To observe two groups of patients with clinical efficacy and adverse reaction. Results The total effective rate of treatment group was 96,75%, control group in the total efficiency was 84.56%, the results showed that there were significant differences between the two groups （P〈0.05）; the rates of the side effects were 10.79% and 8.36%. There were no significant differences between the two groups （P〉0.05）. Conclusion Cefoperazone/sulbactam and levofloxacin in the treatment of community-acquired pneumonia（CAP） can improve the curative effect, and well tolerated.

关 键 词：头孢哌酮-舒巴坦 左氧氟沙星 社区获得性肺炎 

分 类 号：R563.1[医药卫生—呼吸系统]